Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54M
-
Number of holders
-
59
-
Total 13F shares, excl. options
-
20.5M
-
Shares change
-
+3.63M
-
Total reported value, excl. options
-
$374M
-
Value change
-
+$66.4M
-
Number of buys
-
38
-
Number of sells
-
-12
-
Price
-
$18.29
Significant Holders of Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) as of Q2 2020
62 filings reported holding FULC - Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2020.
Fulcrum Therapeutics, Inc. - Common Stock, par value $0.001 per share (FULC) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20.5M shares
of 54M outstanding shares and own 37.85% of the company stock.
Largest 10 shareholders include TRV GP III, LLC (5.96M shares), TRV GP IV, LLC (2.34M shares), FMR LLC (1.85M shares), Casdin Capital, LLC (1.44M shares), Foresite Capital Management IV, LLC (1.13M shares), PERCEPTIVE ADVISORS LLC (894K shares), EcoR1 Capital, LLC (882K shares), BOXER CAPITAL, LLC (706K shares), Alphabet Inc. (682K shares), and BlackRock Inc. (670K shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.